12 December 2024
EMA/CHMP/559432/2024
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Flucelvax Tetra

influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

On 12 December 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Flucelvax Tetra. The marketing authorisation holder for this medicinal product is Seqirus Netherlands B.V.

The CHMP adopted an extension to the existing indication to include vaccination of children from 6 months of age, as follows:[2]

> Prophylaxis of influenza in adults and children from ~~2 years~~**6 months** of age.

For information, the full indication will be as follows:

> Prophylaxis of influenza in adults and children from 6 months of age.
>
> Flucelvax Tetra should be used in accordance with official recommendations.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR) and made available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in bold, removed text as strikethrough

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union